Timing of Onset of Garadacimab for Preventing Hereditary Angioedema Attacks

STAUBACH, Petra, Raffi TACHDJIAN, H. Henry LI, Roman HAKL, Emel AYGÖREN-PÜRSÜN, Lolis WIEMAN, Lawo JOHN-PHILIP and Timothy J. CRAIG. Timing of Onset of Garadacimab for Preventing Hereditary Angioedema Attacks. Clinical & Experimental Allergy. Hoboken: Wiley, 2024. ISSN 0954-7894. Available from: https://dx.doi.org/10.1111/cea.14568.

Basic information

Original name

Timing of Onset of Garadacimab for Preventing Hereditary Angioedema Attacks

Authors

STAUBACH, Petra, Raffi TACHDJIAN, H. Henry LI, Roman HAKL, Emel AYGÖREN-PÜRSÜN, Lolis WIEMAN, Lawo JOHN-PHILIP and Timothy J. CRAIG

Edition

Clinical & Experimental Allergy, Hoboken, Wiley, 2024, 0954-7894

---

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 6.100 in 2022

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1111/cea.14568

UT WoS

001326559500001

Tags

14110114

Tags

International impact, Reviewed

---

Abstract

V originále

Hereditary angioedema (HAE) is a rare, autosomal dominant disease characterised by recurrent, unpredictable, painful, debilitating and potentially life-threatening attacks. HAE imparts a substantial disease burden that impacts daily activities and extends beyond symptoms directly attributable to HAE attacks, encompassing mental health (anxiety and depression) and psychosocial impacts associated with unpredictable attack recurrence.